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Abstract
Acute ischemic stroke resulting from intracranial vessel occlusion is associated with high
morbidity and mortality. The mainstays of therapy are fibrinolytics and mechanical thrombectomy
in properly selected patients. A new Food and Drug Administration-approved technology to
perform thrombectomy, retrievable stenting, may provide superior revascularization rates and
improved patient outcomes. We analyzed the cumulative human experience reported for the Trevo
Pro Retrieval System (Stryker, Kalamazoo, MI, USA) and the Solitaire FR Revascularization
Device (ev3, Irvine, CA, USA) as the definitive treatment for acute ischemic stroke. A literature
search was undertaken to identify studies using the retrievable stents published up to September
2012. Nineteen studies identified a total of 576 patients treated with either the Trevo (n = 221) or
Solitaire (n = 355) devices. Pooled data analysis identified baseline National Institutes of Health
Stroke Scale scores of 18.5 ± 0.289 (standard error of the mean) and 17.9 ± 0.610, and time to
recanalization of 53.9 ± 23.6 minutes and 59.0 ± 8.0 minutes for the Trevo and Solitaire groups,
respectively. Recanalization was variably defined by individual studies, most commonly achieving
at least a thrombolysis in cerebral infarction score of 2a–3 or a thrombolysis in myocardial
infarction score of 2–3. Revascularization (83%, 82%), mortality (31%, 14%), hemorrhage (8%,
6%), device complications (5%, 6%), and good patient outcomes (51%, 47%) were found with the
Trevo and Solitaire devices, respectively. Preliminary analysis reveals excellent clinical outcomes
for retrievable stent technology. This may be attributable to both high rates of revascularization
with a relatively short time to perfusion restoration.
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1. Introduction
Acute cerebral ischemia is a major cause of morbidity and mortality worldwide. 1-3 The
mainstay of medical therapy is intravenous administration of recombinant tissue
plasminogen activator (rt-PA) to establish revascularization (reperfusion).4 Despite this, the
use of rt-PA is successful in only 46.2% of patients when administered intravenously.5,6 For
patients that do not qualify for rt-PA, or for whom it is not successful, endovascular therapy
can be considered.7
In addition to intra-arterial rt-PA8, endovascular therapies including mechanical
thrombectomy devices have evolved to locally obliterate the occlusive thrombus. In 2004,
the Merci Retriever (Concentric Medical, CA, USA) was approved by the US Food and
Drug Administration (FDA) for mechanical thrombectomy in stroke patients.9 The retriever
has a corkscrew-shaped coil capable of extracting clots from occluded vessels and into the
microcatheter. Another mechanical device, the Penumbra System (Penumbra, CA, USA) is
an alternative approach to mechanical thrombectomy. During treatment with the Penumbra,
a separator (microwire controlled by the operator) is used to dislodge the clot, while
aspiration is applied through a proximal microcatheter.10 Though revascularization rates
with these devices are excellent 7,10-12, clinical outcomes have been discordant.13,14 While
revascularization rates of 48% can be achieved with the Merci Retriever, a modified Rankin
scale (mRS) score of ≤ 2 is observed for only 27.7% of patients at 90 days.11 Similarly, the
Penumbra yields a revascularization rate of 82%, but only 25% of patients have a mRS ≤ 2
at 90 days.15
A new generation of endovascular stroke therapy is now focused on a revolutionary class of
devices known as “stentrievers.” Rather than extracting the clot using a corkscrew device
(Merci Retriever) or aspirating the clot (Penumbra System), stentrievers function by first
deploying a stent within the clot itself. After allowing time for sufficient stent integration
into the clot, the combination of the two is removed. This results in immediate, partial flow
restoration as the stent expands, as compared to previous generation devices that require clot
extraction to establish flow restoration. The devices currently approved by the FDA are the
Solitaire FR Revascularization Device (Solitaire; ev3, Irvine, CA, USA) and the Trevo Pro
Retrieval System (Trevo; Stryker, Kalamazoo, MI, USA). Here, we review the initial
experience with these two members of this revolutionizing class of devices used as single
modality treatment of acute ischemic stroke.
2. Methods
A PubMed and MEDLINE keyword search was conducted to identify studies reporting
treatment of acute ischemic stroke with the Solitaire or Trevo devices, published up to
September 2012. Abstracts were reviewed and prioritized; full papers were reviewed, and
references were obtained as appropriate. Inclusion criteria also required that studies utilized
these devices in human subjects. Exclusion criteria consisted of case studies, studies on non-
humans, utilization of multi-modal endovascular treatment, and the use of these devices for
extra-cranial vascular occlusion. For each study, the device used, number of patients, study
design (prospective or retrospective), and median baseline National Institutes of Health
Stroke Scale (NIHSS) scores were recorded. Further data extracted included the
revascularization rate, as was defined by the scale used by individual study groups to
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indicate success.16-18 Additionally, the mean or median time from groin puncture to
revascularization, symptomatic hemorrhage rate, device-related complication rate, mortality
at follow-up, mRS score at follow-up, and use of intra-arterial fibrinolytics was recorded.
Total final recanalization rate, mortality rate, hemorrhage rate, and percentage of patients
with mRS ≤ 2 for each device were calculated using a weighted average of all available
studies.
3. Results
In total, 26 manuscripts were identified that reported the use of the Trevo or Solitaire
devices. Of these, nine were excluded: one due to incorporation of study subjects into a
more contemporary series, six for the use of multi-modal endovascular treatments, one due
to its nature as a case study, and one because of the emphasis on extra-cranial vascular
occlusion.
The 19 included studies identified a total of 576 patients treated with either the Trevo Pro
Retrieval System (n = 221) 19-22 or the Solitaire FR Revascularization Device (n =
355).20,23-35 Pooled data analysis identified median baseline NIHSS scores of 18.5 ± 0.289
(standard error of the mean) and 17.9 ± 0.610, and time to recanalization of 53.9 ± 23.6
minutes and 59.0 ± 8.0 minutes in the Trevo and Solitaire groups, respectively.
Recanalization was variably defined as specified by individual studies, most commonly
achieving at least a thrombolysis in cerebral infarction (TICI) score of 2a–3 or a
thrombolysis in myocardial infarction score of 2–3. Revascularization (83%, 82%),
mortality (31%, 14%), hemorrhage (8%, 6%), device complications (5%, 6%), and good
patient outcomes (51%, 47%) were found for the Trevo and Solitaire devices, respectively
(Table 1, 2).
4. Discussion
Retrievable stents, known as stentrievers, are a novel technology to perform a mechanical
thrombectomy. Unlike prior devices that required clot extraction to achieve reperfusion,
stentrievers facilitate the immediate restoration of blood flow via expansion of a stent within
the clot. The stent integration into the clot also allows for subsequent clot and stent
extraction, without any need for permanent device implantation.
In one of the largest randomized trials, angiographic, safety, and clinical outcomes were
better for the Solitaire device compared with the Merci device. 33 Fundamentally, it is
advantageous to utilize thrombectomy devices with faster revascularization times, as the old
adage “time is brain” is important when maximizing clinical outcomes.36 Other technical
aspects of stentrievers, such as their unlikelihood to result in distal embolization during
treatment, may contribute to the improved clinical outcome. While the results of the study
by Saver et al. are promising 33, (along with similar results identified in other studies),
cautious optimism must be exercised with any proposed radical change in clinical
management. It is increasingly being recognized that any single source, no matter the quality
of the study, should not be used to guide clinical management. 37,38 The “gold standard” for
clinical efficacy is really the reproducibility of any comparison between groups. With this in
mind, stentrievers are on a trajectory to result in a paradigm change in the treatment of
stroke.
Currently, two clinical trials are registered at ClinicalTrials.gov for the Trevo device, both of
which are complete. The TREVO study (NCT01088672) was completed in September 2012
and the final results are yet to be published. The TREVO2 study (NCT01270867) recently
published its results, establishing stentrievers as highly effective thrombectomy devices.19
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Multiple clinical trials, encompassing hundreds of patients, are also ongoing or planned for
the Solitaire device (NCT01657461, NCT00359424, NCT01692379, NCT01327989,
NCT01492725). Stentriever technology is poised to become the preferred mechanical
thrombectomy device in most patients pending evaluation by further randomized trials.
4.1 Illustrative patient
An 83-year-old woman with a history of atrial fibrillation, hypertension, and diabetes
mellitus presented to an outside hospital emergency department (ED) 2 hours after acute-
onset right face, arm, and leg weakness with dysarthia and aphasia. Her NIHSS score on
arrival was 15. Intravenous rt-PA was administered at 0.9 mg/kg over 1 hour beginning 2
hours and 18 minutes after her symptom onset. The patient was subsequently transferred to
our institution’s ED, where her NIHSS score was 16.
MRI demonstrated restricted diffusion in the left corona radiata (Fig. 1A, B) with an infarct
volume of less than 20 cc. There was no evidence of hemorrhage. Magnetic resonance
angiography showed complete occlusion of the mid-M1 segment of the left middle cerebral
artery (MCA; Fig. 1C). The patient was emergently transferred to the neuroendovascular
suite, where intra-arterial therapy commenced 5 hours and 25 minutes after symptom onset.
Catheter-based angiography confirmed complete left mid-M1 segment occlusion (arterial
occlusive lesion [AOL] = 0, TICI = 0; Fig. 2A). A 4 mm × 20 mm Solitaire device was
deployed (Fig. 2B) across the occlusive lesion at 6 hours and 20 minutes following symptom
onset. Following a single pass of the Solitaire device, angiography confirmed virtually
complete recanalization of the left MCA (AOL = III, TICI = 3; Fig. 2C). The stent/clot
combination was extracted. Gross analysis of the Solitaire device demonstrated clot
fragments within the stent retrieval system (Fig. 3).
Post-procedurally, the patient was admitted to the neurosciences intensive care unit for
further monitoring. After CT scanning of the head demonstrated no hemorrhage 24 hours
after rt-PA administration, the patient was started on systemic anti-coagulation given her
history of atrial fibrillation for secondary stroke prevention. She was discharged to a
rehabilitation center on hospital day 6 with a NIHSS score of 5 (mild word-finding
difficulty; mild right face, arm, and leg weakness; mild dysarthia).
5. Conclusions
High recanalization rates and good clinical outcome rates are found in patients treated with
stentrievers. Ongoing and planned clinical trials for the Trevo and Solitaire devices will
further define and confirm their efficacy.
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Fig. 1.
Axial MRI showing restricted diffusion on (A) diffusion weighted imaging and (B) apparent
diffusion coefficient imaging in the left corona radiate with an infarct volume of less than 20
cc. There was no evidence of hemorrhage. (C) Magnetic resonance angiography showed
complete occlusion of the mid-M1 segment of the left middle cerebral artery.
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Fig. 2.
(A) Catheter-based angiography showing complete left mid-M1 segment occlusion (Arterial
Occlusive Lesion [AOL] = 0, Thrombolysis in Cerebral Infarction [TICI] = 0). (B) A 4 mm
× 20 mm Solitaire FR Revascularization Device (ev3, Irvine, CA, USA) was deployed
across the occlusive lesion at 6 hours and 20 minutes following symptom onset. (C)
Following a single pass of the Solitaire device, angiography confirmed virtually complete
recanalization of the left middle cerebral artery (AOL = III, TICI = 3).
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Fig. 3.
Photograph of gross analysis of the Solitaire device (ev3, Irvine, CA, USA) showing clot
fragments within the stent retrieval system.
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